Source: IM Medical Publimas Digital s.l.
During the Plenary of the Interterritorial Council of the National Health System held last May, the first phase of designation of the centers that opted for the use of drugs with CAR-T therapies was resolved.
Thus, the Hospital Clínic de Barcelona, ??the Gregorio Marañón University Hospital, the Vall d´Hebron Hospital, the Hospital Universitari i Politècnic La Fe, the Salamanca Assistance Complex, the Virgen del Rocío University Hospital in Seville, the Valencia University Hospital and the Hospital de la Santa Creu and Sant Pau were chosen for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBDCG) or with acute lymphoblastic leukemia (ALL) of refractory B-cell in the SNS.
In addition, for both treatments (ALL and LBDCG), two additional centers were appointed with the condition that they will only use CAR-T medications in the event that the activity exceeds the centers that are designated: the ICO Hospital Duran i Reynals and the ICO Hospital Germans Trias i Pujol.
Likewise, the centers chosen for the treatment of pediatric patients with acute lymphoblastic leukemia of refractory B cells in the SNS were the Hospital del Niño Jesús, the Hospital Sant Joan de Déu and the Vall d´Hebron Hospital. Likewise, the University Hospital La Paz in Madrid was proposed as an additional center in pediatrics in the event that the activity exceeds the centers that are designated.
But the list is not closed. In response to the commitment of the Ministry of Health to periodically evaluate hospital applications announced by the communities, new centers have been introduced to carry out this type of therapy. Some of them repeat after being rejected in the first round, while others apply for designation for the first time. At the moment the final resolution is unknown, which was discussed on Tuesday during a meeting that brought together the Ministry and the Autonomous Communities, although it is expected to be announced during the next few days.